Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site

References

• Prusiner S B. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136–144
   PubMed Web of Science ®Google Scholar
• Jeffrey M, Goodsir C M, Bruce M E, McBride P A, Fraser J R. In vivo toxicity of prion protein in murine scrapie. ultrastructural and immunogold studies. Neuropathol Appl Neurobiol 1997; 23: 93–101
   PubMed Web of Science ®Google Scholar
• Peyrin J M, Lasmezas C I, Haik S, Tagliavini F, Salmona M, Williams A, Richie D, Deslys J P, Dormont D. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport 1999; 10: 723–729
   PubMed Web of Science ®Google Scholar
• Bate C, Reid S, Williams A. Killing of prion-damaged neurones by microglia. Neuroreport 2001; 12: 2589–2594
   PubMed Web of Science ®Google Scholar
• Bruce M E, McBride P A, Farquhar C F. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci Lett 1989; 102: 1–6
   PubMed Web of Science ®Google Scholar
• Gray F, Chretien F, Adle-Biassette H, Dorandeu A, Ereau T, Delisle M B, Kopp N, Ironside J W, Vital C. Neuronal apoptosis in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 1999; 58: 321–328
   PubMed Web of Science ®Google Scholar
• Caughey B, Lansbury P T. Protofibrils, pores, fibrils, and neurodegeneration. separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267–298
   PubMed Web of Science ®Google Scholar
• Novitskaya V, Bocharova O V, Bronstein I, Baskakov I V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 2006; 281: 13828–13836
   PubMed Web of Science ®Google Scholar
• Serpell L C, Sunde M, Blake C C. The molecular basis of amyloidosis. Cell Mol Life Sci 1997; 53: 871–887
   PubMed Web of Science ®Google Scholar
• Kocisko D A, Baron G S, Rubenstein R, Chen J, Kuizon S, Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 2003; 77: 10288–10294
   PubMed Web of Science ®Google Scholar
• Kocisko D A, Engel A L, Harbuck K, Arnold K M, Olsen E A, Raymond L D, Vilette D, Caughey B. Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. Neurosci Lett 2005; 388: 106–111
   PubMed Web of Science ®Google Scholar
• Breydo L, Bocharova O V, Baskakov I V. Semiautomated cell-free conversion of prion protein. applications for high-throughput screening of potential antiprion drugs. Anal Biochem 2005; 339: 165–173
   PubMed Web of Science ®Google Scholar
• Maxson L, Wong C, Herrmann L M, Caughey B, Baron G S. A solid-phase assay for identification of modulators of prion protein interactions. Anal Biochem 2003; 323: 54–64
   PubMed Web of Science ®Google Scholar
• Bocharova O V, Breydo L, Parfenov A S, Salnikov V V, Baskakov I V. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol 2005; 346: 645–659
   PubMed Web of Science ®Google Scholar
• Baskakov I V, Legname G, Baldwin M A, Prusiner S B, Cohen F E. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 2002; 277: 21140–21148
   PubMed Web of Science ®Google Scholar
• Sokolowski F, Modler A J, Masuch R, Zirwer D, Baier M, Lutsch G, Moss D A, Gast K, Naumann D. Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein. J Biol Chem 2003; 278: 40481–40492
   PubMed Web of Science ®Google Scholar
• Swietnicki W, Morillas M, Chen S G, Gambetti P, Surewicz W K. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 2000; 39: 424–431
   PubMed Web of Science ®Google Scholar
• Leffers K W, Wille H, Stohr J, Junger E, Prusiner S B, Riesner D. Assembly of natural and recombinant prion protein into fibrils. Biol Chem 2005; 386: 569–580
   PubMed Web of Science ®Google Scholar
• Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 1993; 362: 543–546
   PubMed Web of Science ®Google Scholar
• Salmona M, Malesani P, De Gioia L, Gorla S, Bruschi M, Molinari A, Della Vedova F, Pedrotti B, Marrari M A, Awan T, Bugiani O, Forloni G, Tagliavini F. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106–126. Biochem J 1999; 342(Pt 1)207–214
   PubMedGoogle Scholar
• De Gioia L, Selvaggini C, Ghibaudi E, Diomede L, Bugiani O, Forloni G, Tagliavini F, Salmona M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106–126 of the prion protein. J Biol Chem 1994; 269: 7859–7862
   PubMed Web of Science ®Google Scholar
• Jobling M F, Stewart L R, White A R, McLean C, Friedhuber A, Maher F, Beyreuther K, Masters C L, Barrow C J, Collins S J, Cappai R. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106–126. J Neurochem 1999; 73: 1557–1565
   PubMed Web of Science ®Google Scholar
• Florio T, Paludi D, Villa V, Principe D R, Corsaro A, Millo E, Damonte G, D'Arrigo C, Russo C, Schettini G, Aceto A. Contribution of two conserved glycine residues to fibrillogenesis of the 106–126 prion protein fragment. Evidence that a soluble variant of the 106–126 peptide is neurotoxic. J Neurochem 2003; 85: 62–72
   PubMed Web of Science ®Google Scholar
• Boshuizen R S, Langeveld J P, Salmona M, Williams A, Meloen R H, Langedijk J P. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Anal Biochem 2004; 333: 372–380
   PubMed Web of Science ®Google Scholar
• Sellarajah S, Lekishvili T, Bowring C, Thompsett A R, Rudyk H, Birkett C R, Brown D R, Gilbert I H. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. J Med Chem 2004; 47: 5515–5534
   PubMed Web of Science ®Google Scholar
• Caughey B, Caughey W S, Kocisko D A, Lee K S, Silveira J R, Morrey J D. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics. A common mechanism for anti-TSE compounds?. Acc Chem Res 2006; 39: 646–653
   PubMed Web of Science ®Google Scholar
• Bertsch U, Winklhofer K F, Hirschberger T, Bieschke J, Weber P, Hartl F U, Tavan P, Tatzelt J, Kretzschmar H A, Giese A. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005; 79: 7785–7791
   PubMed Web of Science ®Google Scholar
• Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M, Grazia Bruzzone M, Farina L, Limido L, Rossi G, Giaccone G, Ironside J W, Bugiani O, Salmona M, Tagliavini F. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 2002; 99: 10849–10854
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E, Awan T, De Gioia L, Ragg E, Bugiani O, Salmona M. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000; 300: 1309–1322
   PubMed Web of Science ®Google Scholar
• Soto C, Kindy M S, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 1996; 226: 672–680
   PubMed Web of Science ®Google Scholar
• Soto C, Kascsak R J, Saborio G P, Aucouturier P, Wisniewski T, Prelli F, Kascsak R, Mendez E, Harris D A, Ironside J, Tagliavini F, Carp R I, Frangione B. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355: 192–197
   PubMed Web of Science ®Google Scholar
• Langedijk J P, Fuentes G, Boshuizen R, Bonvin A M. Two-rung model of a left-handed beta-helix for prions explains species barrier and strain variation in transmissible spongiform encephalopathies. J Mol Biol 2006; 360: 907–920
   PubMed Web of Science ®Google Scholar
• Govaerts C, Wille H, Prusiner S B, Cohen F E. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A 2004; 101: 8342–8347
   PubMed Web of Science ®Google Scholar
• Nelson R, Sawaya M R, Balbirnie M, Madsen A O, Riekel C, Grothe R, Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005; 435: 773–778
   PubMed Web of Science ®Google Scholar
• Caughey B, Brown K, Raymond G J, Katzenstein G E, Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]. J Virol 1994; 68: 2135–2141
   PubMed Web of Science ®Google Scholar
• Castillo G M, Lukito W, Wight T N, Snow A D. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999; 72: 1681–1687
   PubMed Web of Science ®Google Scholar
• Jenkins J, Pickersgill R. The architecture of parallel beta-helices and related folds. Prog Biophys Mol Biol 2001; 77: 111–175
   PubMed Web of Science ®Google Scholar
• Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases. Biochem Biophys Res Commun 2006; 339: 577–582
   PubMed Web of Science ®Google Scholar
• Nandi P K, Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch Virol 1999; 144: 1751–1763
   PubMed Web of Science ®Google Scholar
• Yang D S, Serpell L C, Yip C M, McLaurin J, Chrishti M A, Horne P, Boudreau L, Kisilevsky R, Westaway D, Fraser P E. Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention. Amyloid J Protein Fold Dis 2001; 8(Suppl 1)10–19
   PubMedGoogle Scholar
• Wong C, Xiong L W, Horiuchi M, Raymond L, Wehrly K, Chesebro B, Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. Embo J 2001; 20: 377–386
   PubMed Web of Science ®Google Scholar
• Deleault N R, Geoghegan J C, Nishina K, Kascsak R, Williamson R A, Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem 2005; 280: 26873–26879
   PubMed Web of Science ®Google Scholar
• Pan T, Wong B S, Liu T, Li R, Petersen R B, Sy M S. Cell-surface prion protein interacts with glycosaminoglycans. Biochem J 2002; 368: 81–90
   PubMed Web of Science ®Google Scholar
• Warner R G, Hundt C, Weiss S, Turnbull J E. Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 2002; 277: 18421–18430
   PubMed Web of Science ®Google Scholar
• Cardin A D, Weintraub H J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989; 9: 21–32
   PubMedGoogle Scholar
• Gonzalez-Iglesias R, Pajares M A, Ocal C, Espinosa J C, Oesch B, Gasset M. Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol 2002; 319: 527–540
   PubMed Web of Science ®Google Scholar
• Aronoff-Spencer E, Burns C S, Avdievich N I, Gerfen G J, Peisach J, Antholine W E, Ball H L, Cohen F E, Prusiner S B, Millhauser G L. Identification of the Cu2+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 2000; 39: 13760–13771
   PubMed Web of Science ®Google Scholar
• Walter E D, Chattopadhyay M, Millhauser G L. The affinity of copper binding to the prion protein octarepeat domain. evidence for negative cooperativity. Biochemistry 2006; 45: 13083–13092
   PubMed Web of Science ®Google Scholar
• Bocharova O V, Breydo L, Salnikov V V, Baskakov I V. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 2005; 44: 6776–6787
   PubMed Web of Science ®Google Scholar
• Ricchelli F, Buggio R, Drago D, Salmona M, Forloni G, Negro A, Tognon G, Zatta P. Aggregation/fibrillogenesis of recombinant human prion protein and Gerstmann-Straussler-Scheinker disease peptides in the presence of metal ions. Biochemistry 2006; 45: 6724–6732
   PubMed Web of Science ®Google Scholar
• Gaggelli E, Bernardi F, Molteni E, Pogni R, Valensin D, Valensin G, Remelli M, Luczkowski M, Kozlowski H. Interaction of the human prion PrP(106–126) sequence with copper(II), manganese(II), and zinc(II). NMR and EPR studies. J Am Chem Soc 2005; 127: 996–1006
   PubMed Web of Science ®Google Scholar
• Haik S, Peyrin J M, Lins L, Rosseneu M Y, Brasseur R, Langeveld J P, Tagliavini F, Deslys J P, Lasmezas C, Dormont D. Neurotoxicity of the putative transmembrane domain of the prion protein. Neurobiol Dis 2000; 7: 644–656
   PubMed Web of Science ®Google Scholar
• Fields C G, Lloyd D H, Macdonald R L, Otteson K M, Noble R L. HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res 1991; 4: 95–101
   PubMedGoogle Scholar
• Evans K C, Berger E P, Cho C G, Weisgraber K H, Lansbury P T, Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation. implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 763–767
   PubMed Web of Science ®Google Scholar
• Familian A, Boshuizen R S, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 2006; 53: 233–240
   PubMed Web of Science ®Google Scholar
• Farquhar C F, Dickinson A G. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986; 67(Pt 3)463–473
   PubMedGoogle Scholar
• Kimberlin R H, Walker C A. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 1986; 30: 409–413
   PubMed Web of Science ®Google Scholar
• McBride P A, Wilson M I, Eikelenboom P, Tunstall A, Bruce M E. Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp Neurol 1998; 149: 447–454
   PubMed Web of Science ®Google Scholar
• Perez M, Wandosell F, Colaco C, Avila J. Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Biochem J 1998; 335(Pt 2)369–374
   PubMedGoogle Scholar
• Gasset M, Baldwin M A, Lloyd D H, Gabriel J M, Holtzman D M, Cohen F, Fletterick R, Prusiner S B. Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A 1992; 89: 10940–10944
   PubMed Web of Science ®Google Scholar
• Petty S A, Adalsteinsson T, Decatur S M. Correlations among morphology, beta-sheet stability, and molecular structure in prion peptide aggregates. Biochemistry 2005; 44: 4720–4726
   PubMed Web of Science ®Google Scholar
• Kretzschmar H A, Stowring L E, Westaway D, Stubblebine W H, Prusiner S B, Dearmond S J. Molecular cloning of a human prion protein cDNA. Dna 1986; 5: 315–324
   PubMedGoogle Scholar